Partnerships
ShilpaBio aims to maximize the access of its products to worldwide patients through creative partnership structures for mutual success.
We aim to solve complex problems in drug discovery, drug development, cell-line development with new-age CDM services. We are open to opportunities to pitch in our scientific skills to the meeting our partners’ objective. If you are interested in partnering with ShilpaBio, please contact us at [email protected]
ShilpaBio partners with biopharmaceutical leaders to enhance our reputation as a preferred contract manufacturing services in Covid-19 vaccines.
Business Announcement
Shilpa Biologicals Partners with Sun Pharmaceuticals
Date: 13 July 2023
Shilpa Biologicals Pvt Ltd. (SBPL) is pleased to announce a strategic partnership with Sun Pharmaceuticals Industries Ltd. for the India region. This collaboration marks a significant milestone in SBPL's mission to expand access to high-quality biosimilars in the Indian market.
Under the terms of the agreement, Shilpa Biologicals will serve as the licensor and grant Sun Pharmaceuticals a license to market and sell Adalimumab, a key biosimilar product. Shilpa Biologicals will be responsible for supplying the product to Sun Pharma, who will leverage its extensive market presence and distribution network to bring Adalimumab to patients across India.
This licensing and supply agreement underscores SBPL's commitment to providing innovative therapeutic solutions while enabling Sun Pharmaceuticals to enhance its product offerings in the biologics segment. With this collaboration, both companies aim to improve patient access to essential biologics, addressing critical healthcare needs in India.
In May2021, Shilpa Biologicals announced in a partnership with Dr.Reddy’s Laboratories to manufacture and supply Drug Substance and Final Product of Sputnik vaccine.
In Aug2021, Shilpa Biologicals announced in a partnership with Zydus Cadilla to manufacture and supply Drug Substance of ZyCov vaccine.
